Learning Objectives:

  1. Describe the presentation and epidemiology of ATTR cardiac amyloidosis, particularly the V122I (pV142I) TTR



  1. Understand the diagnostic pathway and challenges/limitations to non-invasive diagnosis of ATTR cardiac


  1. Outline available treatments for ATTR cardiac amyloidosis, measurements of efficacy, and future agents in current trial.
Session date: 
12/08/2023 - 12:00pm to 1:00pm CST
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Frederick Ruberg, MD